컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

2025 American Society of Clinical Oncology (ASCO) Annual Meeting

30 May - 03 June, 2025, United States

Add-on olanzapine prevents RT-induced nausea, vomiting

2025-09-16

In patients undergoing abdominal-pelvic radiation therapy (RT), treatment with olanzapine along with an antiemetic medication leads to a substantial decrease in RT-induced nausea and vomiting (RINV), with no serious adverse effects, reports a study presented at ASCO 2025.
AMPLITUDE: Niraparib plus AAP improves survival in mCSPC patients with gene mutations

2025-09-16

The combination of niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) results in significant improvements in radiographic progression-free survival (rPFS) and time to symptomatic progression (TSP) in metastatic castration-sensitive prostate cancer (mCSPC) patients with alterations in homologous recombination repair (HRR) genes, as shown by the results of the phase III AMPLITUDE trial.
ARANOTE: Darolutamide positively impacts HRQoL in men with mHSPC

2025-09-16

Darolutamide demonstrated clinically meaningful delays in pain progression and deterioration of important patient-relevant health-related quality of life (HRQoL) outcomes vs placebo in men with metastatic hormone-sensitive prostate cancer (mHSPC), according to phase III ARANOTE trial findings presented at ASCO 2025. [ASCO 2025, abstract 5004]
DeLLphi-304: Tarlatamab bests SoC chemo as 2L treatment for SCLC

2025-09-16

Tarlatamab was associated with significant improvements in overall survival (OS), progression-free survival (PFS) and patient-reported outcomes (PROs) vs standard-of-care (SoC) chemotherapy in patients with small-cell lung cancer (SCLC) undergoing second-line (2L) therapy, according to the primary analysis of the phase III DeLLphi-304 study presented at ASCO 2025.
DESTINY-Breast09: T-DXd plus pertuzumab improves PFS in HER2+ breast cancer

2025-09-16

Treatment with trastuzumab deruxtecan (T-DXd) plus pertuzumab significantly improved progression-free survival (PFS) in patients with HER2+ advanced/metastatic breast cancer (a/mBC) compared with standard of care in the first-line setting, according to a planned interim analysis of the phase III DESTINY-Breast09 trial presented at ASCO 2025.
First-line benmelstobart?anlotinib combo yields PFS gain in advanced PD-L1-positive NSCLC

2025-09-16

In the first-line treatment of patients with advanced PD-L1?positive non?small cell lung cancer (NSCLC), the combination of the anti-PD-L1 monoclonal antibody benmelstobart plus the multikinase inhibitor anlotinib prolongs progression-free survival (PFS) compared with pembrolizumab monotherapy, according to the phase III CAMPASS study conducted in China.
Pembrolizumab + CCRT ups survival in high-risk LACC

2025-09-16

Treatment with the combination of pembrolizumab and concurrent chemoradiotherapy (CCRT), followed by pembrolizumab maintenance, led to a sustained, long-term survival benefit in patients with high-risk, locally advanced cervical cancer (LACC) compared with CCRT alone, according to the final analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at ASCO 2025.
Platinum-resistant ovarian cancer gets survival boost with add-on relacorilant

2025-09-16

Adding the first-in-class selective glucocorticoid receptor antagonist relacorilant to nab-paclitaxel results in improved survival outcomes for patients with platinum-resistant ovarian cancer, as shown in the topline results of the phase III ROSELLA study.
Ropeginterferon α-2b extends benefit to another rare blood cancer

2025-09-16

Topline results of the phase III SURPASS-ET trial show the superior efficacy of ropeginterferon α-2b (ropeg) compared with anagrelide as second-line (2L) treatment for high-risk essential thrombocythaemia (ET), a rare blood cancer that may progress to myelofibrosis or acute myeloid leukaemia.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브